Cargando…

Pituitary Adenlylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieu

Hypoglycaemia is a common side-effect of glucose-lowering therapies for type-2 diabetic patients, which may cause cognitive/neurological impairment. Although the effects of hypoglycaemia in the brain have been extensively studied in neurons, how hypoglycaemia impacts the viability of adult neural st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mansouri, Shiva, Lietzau, Grazyna, Lundberg, Mathias, Nathanson, David, Nyström, Thomas, Patrone, Cesare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909203/ https://www.ncbi.nlm.nih.gov/pubmed/27305000 http://dx.doi.org/10.1371/journal.pone.0156867

Ejemplares similares

PACAP Protects Adult Neural Stem Cells from the Neurotoxic Effect of Ketamine Associated with Decreased Apoptosis, ER Stress and mTOR Pathway Activation
por: Mansouri, Shiva, et al.
Publicado: (2017)

Western Diet Accelerates the Impairment of Odor-Related Learning and Olfactory Memory in the Mouse
por: Lietzau, Grazyna, et al.
Publicado: (2020)

Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4
por: Lietzau, Grazyna, et al.
Publicado: (2016)

Clozapine protects adult neural stem cells from ketamine-induced cell death in correlation with decreased apoptosis and autophagy
por: Lundberg, Mathias, et al.
Publicado: (2020)

The Stroke-Induced Increase of Somatostatin-Expressing Neurons is Inhibited by Diabetes: A Potential Mechanism at the Basis of Impaired Stroke Recovery
por: Chiazza, Fausto, et al.
Publicado: (2020)

Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4
por: Larsson, Martin, et al.
Publicado: (2016)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
por: Darsalia, Vladimer, et al.
Publicado: (2019)

A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia
por: Lietzau, Grazyna, et al.
Publicado: (2021)

Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
por: Lietzau, Grazyna, et al.
Publicado: (2018)

The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
por: Chiazza, Fausto, et al.
Publicado: (2018)

More than Addiction—The Nucleus Accumbens Contribution to Development of Mental Disorders and Neurodegenerative Diseases
por: Bayassi-Jakowicka, Martyna, et al.
Publicado: (2022)

DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes–Induced Blood–Brain Barrier Leakage and Normalize Capillary Pericyte Coverage
por: Elabi, Osama F., et al.
Publicado: (2023)

Sex, Diastolic Blood Pressure, and Outcome after Thrombolysis for Ischemic Stroke
por: Nathanson, David, et al.
Publicado: (2014)

New Hypoglycaemic Therapies
por: Gale, Edwin A M
Publicado: (2000)

Pituitary Adenylate Cyclase-Activating Polypeptide: A Promising Neuroprotective Peptide in Stroke
por: Fang, Yuanjian, et al.
Publicado: (2020)

Pituitary adenylate cyclase activating polypeptide and migraine
por: Zagami, Alessandro S, et al.
Publicado: (2014)

Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina
por: Nakamachi, Tomoya, et al.
Publicado: (2012)

Pituitary Adenylate Cyclase Activating Peptide (PACAP) Participates in Adipogenesis by Activating ERK Signaling Pathway
por: Arsenijevic, Tatjana, et al.
Publicado: (2013)

Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide
por: Atlasz, Tamas, et al.
Publicado: (2018)

Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide
por: Debbabi, Somia, et al.
Publicado: (2018)

Pituitary Adenylate Cyclase Activating Peptide and Post-traumatic Stress Disorder: From Bench to Bedside
por: Riser, Manessa, et al.
Publicado: (2022)

New Evidence for the Role of Pituitary Adenylate Cyclase-Activating Polypeptide as an Antimicrobial Peptide in Teleost Fish
por: Velázquez, Janet, et al.
Publicado: (2023)

Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases
por: Solés-Tarrés, Irene, et al.
Publicado: (2020)

Role of pituitary adenylate cyclase‐activating polypeptide in modulating hypothalamic‐pituitary system
por: Oride, Aki, et al.
Publicado: (2018)

HYPOGLYCAEMIC PROPERTY OF SHILAJEET AND YASHADA BHASMA
por: Bharati,, et al.
Publicado: (1996)

YASADA BHASMA : AN EFFECTIVE HYPOGLYCAEMIC DRUG
por: Prasad, C.M., et al.
Publicado: (1989)

Pituitary Adenylate Cyclase-Activating Polypeptide in Learning and Memory
por: Gilmartin, Marieke R., et al.
Publicado: (2021)

Stress-related disorders, pituitary adenylate cyclase—activating peptide (PACAP)ergic system, and sex differences
por: Ramikie, Teniel S., et al.
Publicado: (2016)

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis
por: Christensen, Casper Emil, et al.
Publicado: (2022)

Increased pituitary adenylate cyclase-activating peptide genes expression in the prefrontal cortex in schizophrenia in relation to suicide
por: Slabe, Zala, et al.
Publicado: (2023)

Oral Hypoglycaemic Agents: The First Thirty Years
por: Nabarro, John D. N.
Publicado: (1992)

Tracing the Origins of the Pituitary Adenylate-Cyclase Activating Polypeptide (PACAP)
por: Cardoso, João C. R., et al.
Publicado: (2020)

Effects of Pituitary Adenylate Cyclase Activating Polypeptide on Cell Death
por: Horvath, Gabriella, et al.
Publicado: (2022)

Pituitary Adenylate Cyclase-Activating Polypeptide Protects Glomerular Podocytes from Inflammatory Injuries
por: Sakamoto, Kenichi, et al.
Publicado: (2015)

Editorial: Novel Therapeutic Potential for Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), Vasoactive Intestinal Peptide (VIP) and Related Peptides in Cognition Deficits
por: Ciranna, Lucia, et al.
Publicado: (2021)

Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases
por: Lee, Eun Hye, et al.
Publicado: (2014)

Corrigendum: Tracing the Origins of the Pituitary Adenylate-Cyclase Activating Polypeptide (PACAP)
por: Cardoso, João C. R., et al.
Publicado: (2020)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

HYPOGLYCAEMIC ACTION OF MOMORDICA CHARANTIA IN NORMAL AND DIABETIC MICE
por: Kavimani, S., et al.
Publicado: (1997)

The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents
por: Tsang, Man-Wo
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_aug1gki9tktdk3qd3f6oei0fms